NOVORAPID 100 UNIT — DIN 02377209
INSULIN ASPART : 100 UNIT · NOVO NORDISK CANADA INC · SOLUTION · wholesale supply in Canada
Health Canada status: CANCELLED POST MARKET
What is NOVORAPID?
NOVORAPID 100 UNIT contains INSULIN ASPART : 100 UNIT. It is listed in the Health Canada Drug Product Database under DIN 02377209, held by NOVO NORDISK CANADA INC, supplied as SOLUTION for SUBCUTANEOUS administration. Health Canada currently lists it as cancelled post market, status dated 16-Aug-2023. This Drug Identification Number is no longer authorized for sale in Canada, so Nexara does not supply it. The record is kept here because buyers still meet the number on old formularies, purchase orders and tender documents; Nexara can help identify an authorized alternative.
What is NOVORAPID used for?
Treatment of patients with diabetes mellitus who require insulin for the control of hyperglycemia.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Insulin Aspart cost around the world?
Insulin Aspart is listed on 3 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Greece publishes a producer price (ex-factory); Norway publishes a max AUP (pharmacy retail); South Africa publishes a single exit price. Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Greece | producer price (ex-factory) | 41 | 41 | EUR███.██ |
| Norway | max AUP (pharmacy retail) | 5 | 6 | NOK███.██ |
| South Africa | single exit price | 1 | 2 | ZAR███.██ |
49 pack listings across 47 brand entries and 3 price bases, refreshed 07 Sep 2026. Ranges span every Insulin Aspart pack in that market, so a high figure is usually a larger pack rather than the same product.
This table is a regulatory record of where the molecule is listed. The DIN on this page is no longer authorized for sale in Canada, so Nexara does not quote it — see the alternatives above.
Is there a generic Insulin Aspart in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
3 holders have a Canadian DIN containing Insulin Aspart, across 11 DINs, of which 8 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| NOVO NORDISK CANADA INC | 6 | 4 | FIASP, NOVORAPID | Sourceable in Canada |
| SANOFI-AVENTIS CANADA INC | 3 | 3 | TRURAPI | Sourceable in Canada |
| BIOCON SDN.BHD | 2 | 1 | KIRSTY | Sourceable in Canada |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 100 UNIT |
|---|---|
| Dosage form | SOLUTION |
| Route | SUBCUTANEOUS |
| Pack configuration (monograph) | 10 mL vials, 3 mL Penfill cartridges, and NovoRapid FlexTouch disposable pens. Pack sizes: 1 x 10 mL (vial), 1 x 3 mL, and 5 x 3 mL (others). |
| Storage | Not explicitly detailed in the provided text snippet (refer to section 11), but standard insulin storage usually applies. |
Pack detail is kept as a regulatory record. This DIN is no longer authorized for sale in Canada, so Nexara does not quote this pack.
Substance and classification
| Active substance | Insulin Aspart |
|---|---|
| ATC code | A10AB05 |
| AHFS class | 68:20.08 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02377209 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2377209 |
| Brand name | NOVORAPID |
| Generic / active ingredient | INSULIN ASPART : 100 UNIT |
| Market authorization holder | NOVO NORDISK CANADA INC |
| Health Canada schedule | Schedule D |
| ATC code | A10AB05 |
| ATC anatomical main group | A — Alimentary tract and metabolism |
| ATC therapeutic subgroup | A10AB |
| Current status | CANCELLED POST MARKET |
| Status date | 16-Aug-2023 |
| Original market date | 2012-05-04 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Individualized dose (usually 0.5-1.0 units/kg/day). Administer SC 5-10 min before or immediately after a meal. Rotate injection sites. Can be used in CSII pump systems (10 mL vials).
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
During episodes of hypoglycemia; patients who are hypersensitive to this drug or to any ingredient in the formulation.
Warnings and precautions
Hypoglycemia risk; uncorrected reactions can be fatal. Rapid onset requires immediate meal. Do not share devices. Risk of hypokalemia. Check labels to avoid medication errors.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
8 of 11 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| FIASP | 100 UNIT | SOLUTION | NOVO NORDISK CANADA INC | MARKETED | 02460408 |
| FIASP | 100 UNIT | SOLUTION | NOVO NORDISK CANADA INC | MARKETED | 02460416 |
| KIRSTY | 100 UNIT | SOLUTION | BIOCON SDN.BHD | MARKETED | 02520974 |
| NOVORAPID | 100 UNIT | SOLUTION | NOVO NORDISK CANADA INC | MARKETED | 02245397 |
| NOVORAPID | 100 UNIT | SOLUTION | NOVO NORDISK CANADA INC | MARKETED | 02244353 |
| TRURAPI | 100 UNIT | SOLUTION | SANOFI-AVENTIS CANADA INC | MARKETED | 02529254 |
| TRURAPI | 100 UNIT | SOLUTION | SANOFI-AVENTIS CANADA INC | MARKETED | 02506564 |
| TRURAPI | 100 UNIT | SOLUTION | SANOFI-AVENTIS CANADA INC | MARKETED | 02506572 |
| FIASP | 100 UNIT | SOLUTION | NOVO NORDISK CANADA INC | DORMANT | 02460424 |
| KIRSTY | 100 UNIT | SOLUTION | BIOCON SDN.BHD | APPROVED | 02520982 |
2 · Same class — other molecules in ATC A10AB
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Insulin Lispro | ADMELOG · ADMELOG SOLOSTAR · HUMALOG · HUMALOG (CARTRIDGE) · +4 more | 13 | 8 | Yes |
| Insulin Aspart | FIASP · KIRSTY · NOVORAPID · TRURAPI | 11 | 8 | Yes |
| Insulin (Human) | HUMULIN R · HUMULIN R (KWIKPEN) · HUMULIN R CARTRIDGE · ILETIN INSULIN REGULAR 100UNIT/ML · +5 more | 9 | 4 | Yes |
| Insulin Glulisine | APIDRA | 4 | 3 | Yes |
| Insulin (Pork) | HYPURIN REGULAR INSULIN PORK · REGULAR PURIFIED PORK INSULIN INJ | 2 | 1 | Yes |
| Insulin (Beef) | SULPHATED INSULIN INJ LIQ 100U/ML | 1 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC A10A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| A10AE | Insulin (Human) · Insulin Degludec · Insulin Degludec And Liraglutide · Insulin Detemir · Insulin Glargine · +2 more | 23 | 15 |
| A10AD | Insulin (Human) · Insulin Aspart · Insulin Lispro | 31 | 9 |
| A10AC | Insulin (Human) · Insulin (Pork) | 13 | 5 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is NOVORAPID called?
The same molecule, Insulin Aspart, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Actrapid HM (ge) | Latin | South Africa |
| Insuman Rapid | Latin | Norway |
| Humulin NPH | Latin | Norway |
| Humulin NPH KwikPen | Latin | Norway |
| Insuman Infusat | Latin | Norway |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.